23/03/2022 - Events
From 25 April to 20 June, 2022, the series "Our brain, that great unknown" will be held in various libraries across Barcelona, supported by the Barcelona library network. This series is part of the "Visions of Science" project organised by the Barcelona Library network, and for the third year it has been entrusted to the Hospital del Mar Medical Research Institute (IMIM) thanks to the success of previous editions. The series will run for 8 weeks. Every Monday at 6:30 pm there will be free talks, open to everyone, on topics related to the brain, a complex and fascinating organ about which we still have a great deal to discover. In this series we will learn about the latest data provided by new scientific advances in this field thanks to the participation of leading experts from Hospital del Mar and the IMIM. We will find out everything from how the brain works and how it behaves in the face of illness to how emotions are seen in the brain and the latest brain surgery techniques.
13/05/2019 - Events
BSC, UPC and IMIM organize the first Advances in Computational Biology conference will bring together researchers working on systems biology, omics technologies, artificial intelligence and high-performance computing (HPC) with applications to biology from both the public and the private sectors. The conference will be held November 28-29 in La Pedrera (Barcelona). Maria Jose Rementeria, Social Link Analytics group leader at the Barcelona Supercomputing Center (BSC) and one of the organizers, states: "One of the main purposes of the conference is to visualize and promote the research done by women scientists and for this reason all presenters will be women, although the conference is open to everyone. We want to create a space to foster collaborations between scientists, providing a unique opportunity to share ideas and build research networks".
Més informació "A conference to promote women's research in computational biology"
Immunotherapy, the use of the patient's own immune system to attack tumour cells is the method chosen by the Hospital del Mar and its research centre, the Hospital del Mar Medical Research Institute (IMIM) in their search for new breast cancer treatments. They are looking in particular at triple negative breast cancer, one of the most aggressive types, which, in addition, affects younger patients and is the breast tumour with the fewest therapeutic targets for oncologists. This commitment has received a strong boost thanks to the grant the Cancer Research Institute (CRI) has just awarded the project "LCOR orchestrates the differential IFN-a response and immunological properties of triple-negative breast cancer cells", led by Dr. Toni Celià-Terrassa, a researcher in the Molecular Therapy of Cancer group, directed by Dr. Joan Albanell, head of medical oncology at Hospital del Mar and director of the IMIM's Cancer Research programme.
Més informació "Immunotherapy for treating the most aggressive breast cancer"
04/05/2017 - Events
Researchers at the Hospital del Mar Medical Research Institute (IMIM) and the University of Barcelona have uncovered a mutation that makes bone vulnerable to bisphosphonates, drugs used to combat osteoporosis. Instead of strengthening bone and preventing fractures, these medicines induce a critical problem that makes the femur more prone to breaks. This discovery, enormously significant clinically, was published today in the New England Journal of Medicine, the most important biomedical journal in terms of potential impact. Osteoporosis causes fractures that affect up to 40% of people over the age of 50. Bisphosphonates are efficient and cheap, making them the first line of treatment for this condition. Nevertheless, they have been associated with atypical fracturing of the femur. "Despite the rarity of this complication and the fact that many more fractures are prevented than induced, fear of this complication has led to the prescription of these drugs being criticised, especially for long-term treatment", explains study leader Dr. Adolf Díez, emeritus head of internal medicine at Hospital del Mar and a researcher in the musculoskeletal research group at the IMIM.
26/05/2016 - Events
Researchers from the Hospital del Mar Medical Research Institute (IMIM) have, for the first time, demonstrated that measurements of a tobacco-specific nitrosamine in the hair, NNK, correlate with the real risk of exposure to the carcinogens in tobacco smoke in passive smokers. This substance is a much better biomarker than any of the markers measured up to now for assessing this risk and it has been found in higher concentrations in the hair than any other tobacco-specific carcinogen. The study was conducted in collaboration with researchers at the Catalan Institute of Oncology (ICO) and has been published in the journal Scientific Reports. The smoke passive smokers are exposed to differs from the smoke of smokers. Passive smokers are exposed to a lot of chemicals resulting from the combustion of the cigarette, but in addition, certain substances have gone through various activation reactions, making them carcinogenic.
Més informació "Biomarker discovered that measures the risk of cancer in non-smokers"
25/05/2016 - Events
Two translational research studies by the University of Barcelona have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies, published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology , have analysed the molecular processes involved in the IL-17 cytokine –a protein family of the immune system- with samples of patients with psoriasis. These results are important to understand the origins of psoriasis and develop more specific pharmaceutical treatments, since the IL-17 blocking is a new therapeutic strategy which is very effective when controlling this illness. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.
Més informació "New evidence on molecular mechanisms involved in psoriasis outset"
09/05/2014 - Events
Understanding the complex nature of G protein-coupled receptors (GPCR) functionality and exploiting this knowledge for the design of new GPCR modulators has been the central focus of GPCR Spring Conference 2014 organized by the GRIB (IMIM-UPF) researchers Jana Selent and Maria Martí at Barcelona Biomedical Research Park (Barcelona) from 28-30th April. GPCRs are the largest family of proteins involved in signal transduction across membranes and one of the most important pharmaceutical drug target classes.
20/12/2011 - Events
Last 14th December an event was held at the PRBB Auditorium; it was organized by the IMIM Group on Cardiovascular Risk and Nutrition to say goodbye to and thank the participants in the PREDIMED study, their involvement, availability and enthusiasm during the four years over which the project has developed (2003-2011).
Més informació "Bidding farewell to the participants of the PREDIMED study"
09/03/2011 - Events
Although thousands of people commit suicide worldwide each year, researchers and doctors do not have any method for evaluating a person's likelihood of thinking about or trying to commit suicide. An international group of scientists, in which the IMIM (Hospital del Mar Research Institute) has participated, has devised the first risk index in order to prevent suicides.
Més informació "First international index developed to predict suicidal behavior"
16/04/2010 - Events
The International Cancer Genome Consortium, which will study the genomes of more than 25,000 cancer patients, has presented its latest research results in the journal Nature. The chronic lymphocytic leukemia genome project is coordinated in Spain, and the researcher Nuria López-Bigas, head of Biomedical Genomics laboratory of GRIB (IMIM-UPF) participates on the bioinformatics analysis of data and the coordination and management of Consortium data.
Més informació "The chronic lymphocytic leukaemia project reveals the first oncogenic mutations"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
